Ukr.Biochem.J. 2026; Volume 98, Issue 2, Mar-Apr, pp. 61-68

Cytokine profile of kidneys in rats with experimental hyperhomocysteinemia

A. S. Serbin, T. V. Koval*, O. I. Kharchenko,
L. I. Kot, T. R. Andriichuk

Educational and Scientific Center “Institute of Biology and Medicine”,
Taras Shevchenko National University of Kyiv, Ukraine;
*e-mail: kovaltanya@knu.uat

Received: 19 January 2026; Revised: 29 January 2026;
Accepted: 03 April 2026; Available on-line: April 2026

Hyperhomocysteinemia (HHcy) is a systemic metabolic disorder known to impair renal function. The kidneys play a crucial role in homocysteine (Hcy) clearance from the bloodstream and represent a key location for Hcy-related metabolic disturbances. A principal mechanism underlying Hcy-induced injury of renal tissue is inflammation, however, the age-related renal cytokine profile under HHcy conditions remains insufficiently characterized. Therefore, the aim of this study was to evaluate the level of pro- and anti-inflammatory cytokines in the kidneys of rats of different ages with experimental HHcy. The study was performed on nonlinear male rats divided into groups of young (one-month-old) and adult (six-month-old) animals with HHcy as well as control animals of the same age. HHcy was induced by the daily intragastric administration of D,L-homocysteine thiolactone (200 mg·kg-1 body weight) for eight weeks. At the end of the experimental period, the kidneys were excised for homogenate preparation. The levels of cytokines IL-1β, IL-4, IL-6, IL-8, IL-10, TNF-α, and IFN-γ were determined using ELISA. The renal level of the anti-inflammatory cytokine IL-10 was decreased in both age groups of rats with HHcy relative to control values. In young rats with HHcy, increased renal levels of pro-inflammatory cytokines IL-1β, IL-6 and TNF-α were found, while in adult rats with HHcy, decreased renal levels of IL-6 and TNF-α compared to the age-matched control group were observed. These findings indicate that HHcy induces renal cytokine profile alterations that depend on the age of the animals­.

Keywords: , , , , ,


References:

  1. McCaddon A, Miller JW. Homocysteine-a retrospective and prospective appraisal. Front Nutr. 2023;10:1179807. PubMed, PubMedCentral, CrossRef
  2. Koklesova L, Mazurakova A, Samec M, Biringer K, Samuel SM, Büsselberg D, Kubatka P, Golubnitschaja O. Homocysteine metabolism as the target for predictive medical approach, disease prevention, prognosis, and treatments tailored to the person. EPMA J. 2021;12(4):477-505. PubMed, PubMedCentral, CrossRef
  3. Marroncini G, Martinelli S, Menchetti S, Bombardiere F, Martelli FS. Hyperhomocysteinemia and Disease-Is 10 μmol/L a Suitable New Threshold Limit? Int J Mol Sci. 2024;25(22):12295. PubMed, PubMedCentral, CrossRef
  4. Jakubowski H, Witucki Ł. Homocysteine metabolites, endothelial dysfunction, and cardiovascular disease. Int J Mol Sci. 2025;26(2):746. PubMed, PubMedCentral, CrossRef
  5. Cao X, Wang T, Mu G, Chen Y, Xiang B, Zhu J, Shen Z. Dysregulated homocysteine metabolism and cardiovascular disease and clinical treatments. Mol Cell Biochem. 2025;480(9):4907-4920. PubMed, PubMedCentral, CrossRef
  6. Li B, Kou Y, Zhang L, Yi L. Hyperhomocysteinemia-driven ischemic stroke: unraveling molecular mechanisms and therapeutic horizons. Food Sci Nutr. 2025;13(7):e70517. PubMed, PubMedCentral, CrossRef
  7. Ramires Júnior OV, Prauchner GRK, Rieder AS, Leite AKO, Farias CP, Wyse ATS. Uncovering hyperhomocysteinemia: global risk patterns and molecular disruption in brain and vascular health. J Neurochem. 2025;169(12):e70327. PubMed, PubMedCentral, CrossRef
  8. Son P, Lewis L. Hyperhomocysteinemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. PubMed
  9. Chen W, Liang X, Liang G, Zhao X, Wang J, Jiang Q. Hyperhomocysteinemia and its association with decreased glomerular filtration rate in patients with chronic kidney disease: a comprehensive meta-analysis. PeerJ. 2025;13:e20064. PubMed, PubMedCentral, CrossRef
  10. Rehman T, Shabbir MA, Inam-Ur-Raheem M, Manzoor MF, Ahmad N, Liu ZW, Ahmad MH, Siddeeg A, Abid M, Aadil RM. Cysteine and homocysteine as biomarker of various diseases. Food Sci Nutr. 2020;8(9):4696-4707. PubMed, PubMedCentral, CrossRef
  11. Long Y, Nie J. Homocysteine in renal injury. Kidney Dis (Basel). 2016;2(2):80-87. PubMed, PubMedCentral, CrossRef
  12. Chen W, Feng J, Ji P, Liu Y, Wan H, Zhang J. Association of hyperhomocysteinemia and chronic kidney disease in the general population: a systematic review and meta-analysis. BMC Nephrol. 2023;24(1):247. PubMed, PubMedCentral, CrossRef
  13. Hurjui LL, Tarniceriu CC, Serban DN, Lozneanu L, Bordeianu G, Nedelcu AH, Panzariu AC, Jipu R, Hurjui RM, Tanase DM, Serban IL. Homocysteine attack on vascular endothelium-old and new features. Int J Mol Sci. 2025;26(13):6298. PubMed, PubMedCentral, CrossRef
  14. Tawfik A, Elsherbiny NM, Zaidi Y, Rajpurohit P. Homocysteine and Age-Related Central Nervous System Diseases: Role of Inflammation. Int J Mol Sci. 2021;22(12):6259. PubMed, PubMedCentral, CrossRef
  15. Koçhan E, Celik Z, Uğurlucan M, Önal B, Arslan Ulukan Z. Homocysteine, inflammation, and oxidative stress: reassessing a controversial biomarker in cardiovascular diseases. Int J Basic Clin Stud. 2025;14(2):1-21.
  16. Bhol NK, Bhanjadeo MM, Singh AK, Dash UC, Ojha RR, Majhi S, Duttaroy AK, Jena AB. The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds. Biomed Pharmacother. 2024;178:117177. PubMed, CrossRef
  17. Kravchenko O, Raksha N, Kostiuk O, Liashevska O, Tiron O, Maievskyi O. Impact of hyperhomocysteinemia on cytokine and matrix metalloproteinases contents in rat skeletal muscle. Biomed Biotechnol Res J. 2024;8(3):387-392. CrossRef
  18. Prasad K. Atherogenic effect of homocysteine, a biomarker of inflammation and its treatment. Int J Angiol. 2024;33(4):262-270. PubMed, PubMedCentral, CrossRef
  19. Zhang M, Ni H, Lin Y, Wang K, He T, Yuan L, Han Z, Zuo X. Renal aging and its consequences: navigating the challenges of an aging population. Front Pharmacol. 2025;16:1615681. PubMed, PubMedCentral, CrossRef
  20. Synelnyk T, Raksha N, Kostiuk O, Kharchenko O, Rymsha S, Korol V, Korol A, Bernyk O, Maievskyi O. Proteolytic system parameters in the brain of rats with hyperhomocysteinemia. J Biol Res (Boll Soc Ital Biol Sper). 2024;97(1):12232. CrossRef
  21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72(1-2):248-254. PubMed, CrossRef
  22. Crowther JR. The ELISA guidebook. Methods Mol Biol. 2000;149(III-IV):1-413. PubMed, CrossRef
  23. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023. PubMed, PubMedCentral, CrossRef
  24. Serbin A, Strelkova C, Koval T, Kharchenko O, Andriichuk T. Research of indicators of oxidative stress in the kidneys of immature rats with hyperhomocysteinemia. Bull Taras Shevchenko Natl Univ Kyiv Biol Ser. 2022;91(4): 5-9. CrossRef
  25. Wu C, Duan X, Wang X, Wang L. Advances in the role of epigenetics in homocysteine-related diseases. Epigenomics. 2023;15(15):769-795. PubMed, CrossRef
  26. Xiong J, Ma F, Ding N, Xu L, Ma S, Yang A, Hao Y, Zhang H, Jiang Y. miR-195-3p alleviates homocysteine-mediated atherosclerosis by targeting IL-31 through its epigenetics modifications. Aging Cell. 2021;20(10):e13485. PubMed, PubMedCentral, CrossRef
  27. Tang L, Li L, Liu Y, Zhang X, Wang X, Zheng Z, Yang P, Wu H. Epigenetic modifications in vascular inflammation. Front Immunol. 2025;16:1711579. PubMed, PubMedCentral, CrossRef
  28. Ren L, Pushpakumar S, Almarshood H, Das SK, Sen U. Epigenetic DNA methylation and protein homocysteinylation: key players in hypertensive renovascular damage. Int J Mol Sci. 2024;25(21):11599. PubMed, PubMedCentral, CrossRef
  29. Jakubowski H. Homocysteine thiolactone detoxifying enzymes and Alzheimer’s disease. Int J Mol Sci. 2024;25(15):8095. pm id=”39125665″], PubMedCentral, CrossRef
  30. Wei W, Zhao Y, Zhang Y, Jin H, Shou S. The role of IL-10 in kidney disease. Int Immunopharmacol. 2022;108:108917. PubMed, CrossRef
  31. Raksha N, Maievskyi O, Dzevulska I, Kaminsky R, Samborska I, Savchuk O, Kovalchuk О. Proteolytic activity in the heart of rats with hyperhomocysteinemia. Wiad Lek. 2022;75(4 pt 1):831-835. PubMed, CrossRef
  32. Raksha N, Kostyuk O, Synelnyk T, Kharchenko O, Shchypanskyi S, Gunas I, Nazarova O, Gritsenko A, Andriichuk T, Maievskyi O. Effect of hyperhomocysteinemia on proteolytic activity in the spleen. Biomed Biotechnol Res J. 2023;7(2):170-175. CrossRef
  33. Raksha N, Hryshchenko T, Maievskyi O, Dzevulska I, Kaminsky R, Yushchenko A, Samborska I, Zakharchuk N, Savchuk O, Kovalchuk O. Biochemical disorders in the thyroid gland in rats with hyperhomocysteinemia. Biomed Res Ther. 2022;9(5):5065-5074. CrossRef
  34. Zhang M, Dong R, Da J, Yuan J, Zha Y, Long Y. Hyperhomocysteinemia exacerbates acute kidney injury via increased mitochondrial damage. Front Physiol. 2022;13:967104. PubMed, PubMedCentral, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.